With the help of the US Hereditary Angioedema Association, seven (7) HAE therapies have completed clinical trials, received FDA-approval, and are now available to treat HAE. The HAEA continues to actively support all types of novel HAE research, particularly through the US HAEA Angioedema Center at UCSD. We also encourage pharmaceutical companies to continue to develop new and improve current HAE therapies. The HAEA takes an active role in patient recruitment for clinical trials. We conduct our own unique research, powered by our strong and united patient community, to demonstrate to insurers the quality of life and economic benefits that HAE medicines provide.
The HAE Association continues to advance HAE research, to benefit patients today, and make a brighter tomorrow for future HAE generations.